Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

ISSN： 0945-6317

Source： Virchows Archiv, Vol.453, Iss.2, 2008-08, pp. : 133-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)

By Nishimura

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 47-52

Spandidos Publications

Access to resources Recommend Favorite

Extended trastuzumab therapy improves the survival of HER2positive breast cancer patients following surgery and radiotherapy for brain metastases

Molecular and Clinical Oncology, Vol. 1, Iss. 6, 2013-01 ,pp. : 995-1001

Spandidos Publications

Access to resources Recommend Favorite

Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer

By Woenckhaus Joachim Steger Klaus Sturm Klaus Münstedt Karsten Franke Folker Fenic Irina

Virchows Archiv, Vol. 450, Iss. 4, 2007-04 ,pp. : 387-395

Springer Publishing Company

Access to resources Recommend Favorite

Somatic mutation in PIK3CA is a late event in cervical carcinogenesis

The Journal Of Pathology: Clinical Research, Vol. 1, Iss. 4, 2015-10 ,pp. : 207-211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer

By Tozuka

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 93-99

Spandidos Publications

Access to resources Recommend Favorite